Home Markets ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium

ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium

2
investorsdiurnal business news magazine

This post was originally published on this site

<p xmlns="https://www.w3.org/1999/xhtml"><span class="xn-location">HOUSTON and <span class="xn-location">VANCOUVER, BC, <span class="xn-chron">Oct. 24, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today…